Monument Therapeutics secures £850K to advance schizophrenia treatment with MT1988 25 Feb Written by Alexandra Collingbourne Alexandra Collingbourne Previous Previous Sphere Fluidics rebrands to Sphere Bio Next Next Healx doses first subject in Phase II neurofibromatosis type 1 therapy trial
Monument Therapeutics secures £850K to advance schizophrenia treatment with MT1988 25 Feb Written by Alexandra Collingbourne Alexandra Collingbourne
